A common blood pressure medication called hydralazine may cause ANCA-associated vasculitis (AAV), with a severe impact on both…
Articles by Inês Martins, PhD
A rare case of ANCA-associated vasculitis (AAV) causing thickening of the dura mater — a protective membrane of the…
To better understand the concerns and behaviors of people with autoimmune conditions during the COVID-19 pandemic, the Global Healthy…
The multiple sclerosis treatment Lemtrada (alemtuzumab) can cause severe ANCA-associated vasculitis in rare cases, adding to…
High doses of corticosteroids as initial treatment and kidney problems evident at diagnosis significantly increase the likelihood of early…
Among ANCA-associated vasculitis patients in remission — particularly those with manifestations in their kidneys — the reappearance of MPO-ANCA antibodies…
A combination of belimumab plus standard maintenance treatment is no better than standard of care alone at delaying relapse in ANCA-associated…
The immunosuppressant agent mycophenolate mofetil (MMF) is similar to standard cyclophosphamide at inducing remission in ANCA-associated vasculitis (AAV)…
Disease status at three and six months seems to predict long-term survival and kidney failure in patients with ANCA-associated vasculitis…
The U.S. Food and Drug Administration has approved a label update for Rituxan (rituximab) to include information for patients…